Ares Financial Consulting LLC Purchases Shares of 21,026 Pfizer Inc. $PFE

Ares Financial Consulting LLC purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,026 shares of the biopharmaceutical company’s stock, valued at approximately $524,000.

Several other hedge funds also recently modified their holdings of PFE. Triad Wealth Partners LLC boosted its stake in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares in the last quarter. ETF Store Inc. boosted its position in shares of Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after purchasing an additional 396 shares in the last quarter. Mattern Wealth Management LLC grew its stake in shares of Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 400 shares during the period. Quest Investment Management LLC increased its position in Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 405 shares in the last quarter. Finally, Community Bank & Trust Waco Texas increased its position in Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after buying an additional 412 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research note on Monday, March 9th. Finally, Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.48.

Pfizer Trading Down 0.7%

NYSE:PFE opened at $26.81 on Tuesday. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75. The firm has a 50-day moving average price of $27.22 and a two-hundred day moving average price of $26.07. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The firm has a market cap of $152.47 billion, a price-to-earnings ratio of 19.72 and a beta of 0.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.63 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Large dividend yield highlighted — Pfizer’s 6.37% yield is being promoted in dividend-screening pieces, which supports investor demand from income-focused funds and retail buyers. Is Pfizer (PFE) One of the Best Fortune 500 Dividend Stocks to Invest in Right Now?
• Positive Sentiment: Supply agreement tied to promising clinical program — Relay Therapeutics reported supportive triplet data and noted a supply agreement with Pfizer to supply atirmociclib, which could translate to incremental product volumes if the program advances. That commercial tie offers potential near‑term revenue upside if development proceeds. Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
• Positive Sentiment: Featured in high‑yield stock roundups — Pfizer’s inclusion in lists aimed at generating passive income (e.g., 247wallst) can attract yield-seeking capital, providing a supportive technical buyer base for the shares. Want $1,188 in Passive Income? Invest $5,000 Into These 3 High-Yielding Stocks
• Neutral Sentiment: Minor executive movement mention — A former Pfizer commercial quality executive was appointed to Armata’s board; this is notable for career flow but likely immaterial to Pfizer’s fundamentals. Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
• Negative Sentiment: Competition risk from obesity market — Multiple writeups compare Pfizer with Novo Nordisk as the obesity market heats up; Novo’s leadership and pipeline strength could pressure Pfizer’s growth outlook and investor sentiment if Pfizer’s obesity/GLP programs don’t scale as fast. Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.